Alicia Henao Uribe, MD
Hematology & Oncology · Cape Girardeau, MONPI 1295922995
Payments from drug & device makers
Across 111 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$244
- Johnson & Johnson$202
- Incyte Corporation$200
- Seagen Inc.$156
- Bristol Myers Squibb$150
- Merck$137
- plus $2K from 33 others
What the payments were for
- Food & beverage$2,52689%
- Education$29911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $244 |
| Johnson & Johnson | 6 | $202 |
| Incyte Corporation | 8 | $200 |
| Seagen Inc. | 4 | $156 |
| Bristol Myers Squibb | 8 | $150 |
| Merck | 7 | $137 |
| Foundation Medicine, Inc. | 1 | $120 |
| Gilead | 4 | $119 |
| Pfizer | 7 | $117 |
| AbbVie | 6 | $116 |
| Novartis | 6 | $113 |
| Heron Therapeutics, Inc. | 2 | $106 |
| Genentech USA, Inc. | 1 | $83 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Eisai Inc. | 4 | $77 |
| Adaptive Biotechnologies Corporation | 3 | $68 |
| Dendreon Pharmaceuticals LLC | 1 | $65 |
| Amgen | 3 | $58 |
| Lilly USA, LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Morphosys, US Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Sanofi | 2 | $39 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| Beigene USA, Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Tempus AI, Inc | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Bayer | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE LIQUID CDX$120
- LYNPARZA$108
How this compares
$2,825 in reported general payments places this provider in the 45th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 53 | $1,075,886 |
| Lenalidomide | 27 | $666,878 |
| DopteletAvatrombopag Maleate | 13 | $300,479 |
| ImbruvicaIbrutinib | 13 | $212,243 |
| IbrancePalbociclib | 13 | $202,130 |
| VenclextaVenetoclax | 14 | $192,740 |
| TavalisseFostamatinib Disodium | 13 | $187,316 |
| CalquenceAcalabrutinib Maleate | 11 | $151,130 |
| KyprolisCarfilzomib | 30 | $108,697 |
| XareltoRivaroxaban | 22 | $16,958 |
| Abiraterone Acetate | 13 | $13,262 |
| Enoxaparin Sodium | 12 | $5,863 |
| Sucralfate | 17 | $2,814 |
| Imatinib Mesylate | 12 | $1,786 |
| Hydroxyurea | 85 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $150 | $1,075,88653 claims |
| PfizerIbrance | $117 | $202,13013 claims |
| AbbVieVenclexta | $116 | $192,74014 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $16 | $187,31613 claims |
| AstraZenecaCalquence | $244 | $151,13011 claims |
| AmgenKyprolis | $58 | $108,69730 claims |
| Johnson & JohnsonXarelto | $202 | $16,95822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Cape Girardeau
- James MosleyCape Girardeau$1.7M
- Andrew DickeyCape Girardeau$29K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
- Shahzad RazaKansas City$1.7M
- Gerhard HildebrandtColumbia$1.6M
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.